Alkem's Daman Plant Exits FDA Inspection With 7 Form 483 Observations

Alkem Laboratories is now managing the regulatory fallout from a US FDA inspection at its Amaliya manufacturing facility in Daman, which closed on May 1, 2026, with seven observations recorded on a Form 483. For QA directors and plant heads operating under 21 CFR Part 211, the number of observations signals a compliance posture that will require structured, time-bound remediation before the agency issues its Establishment Inspection Report.

The inspection ran from April 20 to May 1, 2026, spanning twelve days at the Daman site. While the specific citation categories have not been publicly disclosed, seven observations at a single facility is a figure that typically reflects systemic gaps rather than isolated procedural lapses. Indian formulation and API plants have faced recurring 483 citations in areas including data integrity, equipment qualification, out-of-specification investigation procedures, and environmental monitoring under sterility assurance programs. Any of these domains, if cited, would require Alkem to submit a comprehensive corrective and preventive action response to the agency within the standard timeframe.

For QA teams managing similar facilities, the Alkem inspection reinforces the importance of pre-inspection readiness programs aligned with ICH Q10 pharmaceutical quality system principles. Mock inspections, live data integrity audits, and cross-functional CAPA governance are among the remediation levers that plant heads should have activated well ahead of an FDA site visit. The agency's inspection cadence at Indian manufacturing sites has remained rigorous, and a 483 with seven observations will be closely watched as Alkem's written response takes shape.

Source: Indian Pharma Post, reporting on a Media4Growth release, published May 3, 2026. Specific observation categories were not disclosed in the source material.